comparemela.com

Latest Breaking News On - Waterlase exclusive trial - Page 1 : comparemela.com

BIOLASE MAINTAINS MOMENTUM AND REPORTS NINTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR GROWTH; REITERATES FULL YEAR GUIDANCE OF AT LEAST 25% REVENUE GROWTH AND PROFITABILITY FOR FULL YEAR 2023

/PRNewswire/ BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the first quarter ended March 31,.

John beaverMichael polyviou todd kehrliBiolase incCompany waterlase exclusive trial programWaterlase exclusive trial programSource biolase incExchange commissionTraining programs introducing broader communityExperience industry leading dental lasersFirst timeWaterlase exclusive trialChief executiveFull year financial guidanceWaterlase expressPrivate securities litigation reform actOperating activities

BIOLASE DELIVERS 24% REVENUE GROWTH IN 2022 AS GO-TO-MARKET STRATEGIES GAIN MOMENTUM; GUIDES FOR AT LEAST 25% REVENUE GROWTH AND PROFITABILITY IN 2023

/PRNewswire/ BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the fourth quarter and full year.

John beaverMichael polyviou todd kehrliPrnewswire biolase incCompany adjustedSource biolase incWaterlase exclusive trial programBiolase incExchange commissionYear financialWaterlase exclusive trialChief executiveFull year financial guidanceWaterlase expressPrivate litigation reform actOperating activitiesInvesting activities

vimarsana © 2020. All Rights Reserved.